Monitor the December 1, 2026 shareholder vote on the ITM merger; approval would create a vertically integrated radiopharmaceutical leader. Also watch for the TLX250-Px BLA resubmission and Pixclara revenue ramp in Q4.
Price Chart
Executive Summary
Telix reported Q3 2026 group revenue of $245M (+19% YoY), with Precision Medicine revenue up 30% to $201M, and reaffirmed FY 2026 revenue guidance at the upper end of $950M-$970M plus $40M other income. The FDA approval of Pixclara for glioma imaging and the transformative ITM merger ($1.65B upfront) are key catalysts, though the merger requires shareholder approval on December 1, 2026.
Key Financial Metrics
Key Facts
- Q3 2026 group revenue $245M, +19% YoY; Precision Medicine revenue $201M, +30% YoY
- FY 2026 revenue guidance reaffirmed at upper end of $950M-$970M plus $40M other income; total expected to exceed $1B
- FDA approved Pixclara for glioma imaging in September 2026; first commercial doses administered
- Announced merger with ITM for $1.65B upfront consideration (cash-free, debt-free); ITM shareholders to receive ~$1.25B in Telix ADRs; up to $700M contingent milestones
- R&D expenditure guidance revised to $240M-$260M (previously $230M-$270M)
- BiPASS Phase 3 study completed enrollment; FDA granted Fast Track Designation and supports NDA pathway
- TLX250-Px (Zircaix) BLA resubmission planned near term after corrected CRL
Financial Impact
Q3 revenue $245M (+19% YoY); FY 2026 revenue guidance $950M-$970M plus $40M other income; ITM merger $1.65B upfront plus $700M contingent
Risk Factors
- ITM merger requires shareholder approval and customary closing conditions; failure would remove a key growth catalyst
- TLX250-Px BLA resubmission dependent on addressing third-party manufacturing observations; further delays possible
- R&D expenditure guidance revised upward, indicating higher near-term cash burn
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3385039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | 6-K | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $8.99 (−10.37%) |
Oct 20, 2026 6d ago | Press Release | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $8.99 (−10.37%) |
Sep 29, 2026 26d ago | 6-K | $10.97 $10.72 | ▼ −2.28% | ▼ −2.46% | $8.99 (−18.05%) |
Sep 21, 2026 5w ago | 6-K | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $8.99 (−20.51%) |
Sep 20, 2026 5w ago | Press Release | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $8.99 (−20.51%) |
Sep 14, 2026 6w ago | 6-K | $12.83 $11.83 | ▼ −7.79% | ▼ −7.35% | $8.99 (−29.93%) |
Sep 14, 2026 6w ago | Press Release | $11.78 $12.83 | ▲ +8.91% | ▲ +9.37% | $8.99 (−23.68%) |
Sep 1, 2026 7w ago | 6-K | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $8.99 (−21.48%) |
Sep 1, 2026 7w ago | Press Release | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $8.99 (−21.48%) |
Aug 19, 2026 9w ago | 6-K | $12.42 $11.33 | ▼ −8.78% | ▼ −9.19% | $8.99 (−27.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers